<DOC>
	<DOC>NCT00688688</DOC>
	<brief_summary>The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.</brief_summary>
	<brief_title>Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder</brief_title>
	<detailed_description>Patients who completed 178-CL-046 (NCT00689104) or 178-CL-047 (NCT00662909) or new patients could be enrolled in this study if eligible.</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patient is willing and able to complete the micturition diary and questionnaires correctly Patient has symptoms of overactive bladder for ≥ 3 months Patient experiences frequency of micturition on average ≥ 8 times per 24hour period during the 3day micturition diary period Patient must experience at least 3 episodes of urgency (grade 3 or 4) with or without incontinence, during the 3day micturition diary period Patient is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control Patient has significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor Patient has an indwelling catheter or practices intermittent selfcatheterization Patient has diabetic neuropathy Patient has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs Patient receives nondrug treatment including electrostimulation therapy Patient has severe hypertension Patient has a known or suspected hypersensitivity to tolterodine, other anticholinergics, YM178, other betaadrenoreceptor (ßAR) agonists, or lactose or any of the other inactive ingredients Patient has been treated with any investigational drug or device within 30 days (90 days in the UK for all clinical studies except 178CL046) Patient had an average total daily urine volume &gt; 3000 mL as recorded in the 3day micturition diary period Patient has serum creatinine &gt;150 umol/L, aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 2x upper limit of normal range (ULN), or gammaglutamyl transpeptidase (γGT) &gt; 3x ULN Patient has a clinically significant abnormal electrocardiogram (ECG)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Frequency</keyword>
	<keyword>Micturition</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Urinary urge incontinence</keyword>
</DOC>